Mission & Vision
Based On The World’s first DNA Aptamer Patent, Becoming A Global Therapeutics and Healthcare Market Leader
Based On The World’s first DNA Aptamer Patent, Becoming A Global Therapeutics and Healthcare Market Leader
Entering the global healthcare market with the start of commercializing the first DNA Aptamer in worldwide
Intellectual Property Status
Area | Applied | PCT | Registered | Total |
---|---|---|---|---|
Aptamin® | 24 | 2 | 7 | 33 |
Therapeutics | 12 | 12 | ||
Early Diagnosis | 5 | 5 | ||
Other | ||||
Total | 41 | 2 | 7 | 50 |
Wayne Lee
ITE Co., V.President
BizInfra Co., CEO
IFS Korea, CEO
IBM Korea
Hanyang University
Eric Sohn
C.P.M / 6Sigma MBB
G. Manager, IMaketKorea
Samsung Fire & Marine Insurance
Yoonsung Kim, M.D., Ph.D.
Rutgers University Medical School
Weill Cornell Medicine
Ph.D. in Medical School, Cornell Univ.
Yeongjeong Kim, Ph.D.
Dept. of Nursing Science,
Kyunghee University
Post-doc. Fellowship, Weill Medical School, Cornell Univ.
Ph.D, Kyunghee University
Jaeryun Kwon
CEO, Winner Study
CEO, Korea M.N.A.
CEO, Korea Corporate Investment Co., Ltd.